Trending NewsTrending NewsNASDAQ:ARDX Ardelyx (ARDX) Stock Price, News & Analysis $3.08 -0.12 (-3.75%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$3.11 +0.03 (+0.94%) As of 10/23/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ardelyx Stock (NASDAQ:ARDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ardelyx alerts:Sign Up Key Stats Today's Range$3.02▼$3.2050-Day Range$3.08▼$4.0652-Week Range$3.02▼$8.40Volume4.81 million shsAverage Volume4.29 million shsMarket Capitalization$767.50 millionP/E RatioN/ADividend YieldN/APrice Target$13.90Consensus RatingModerate Buy Company Overview Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments. Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders. Both products are available in the United States. Founded in 2007, Ardelyx is headquartered in Waltham, Massachusetts. In addition to its commercial products, the company continues to advance an investigational pipeline focused on gastrointestinal and cardiorenal disorders. Ardelyx is led by President and Chief Executive Officer Mike Raab.AI Generated. May Contain Errors. Read More Ardelyx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreARDX MarketRank™: 2.840394351185 of 5 starsArdelyx scored higher than 57% of companies evaluated by MarketBeat, and ranked 407th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArdelyx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialArdelyx has a consensus price target of $13.90, representing about 351.3% upside from its current price of $3.08.Amount of Analyst CoverageArdelyx has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ardelyx's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.21) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -14.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -14.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 4.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ardelyx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.73% of the float of Ardelyx has been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Ardelyx has recently increased by 8.10%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.06 News SentimentArdelyx has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Ardelyx this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $486,588.00 in company stock.Percentage Held by Insiders5.30% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ardelyx's insider trading history. Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARDX Stock News HeadlinesArdelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate BindersOctober 23 at 4:01 PM | globenewswire.comARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawOctober 23 at 11:15 AM | globenewswire.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.October 24 at 1:00 AM | Banyan Hill Publishing (Ad)Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor HarmOctober 22 at 11:00 AM | globenewswire.comARDX Shareholder Alert: November 16, 2026 Lead Plaintiff Deadline in Ardelyx, Inc. Securities Class Action - Contact SueWallStOctober 22 at 10:11 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDXOctober 22 at 10:00 AM | prnewswire.comPiper Sandler Reaffirms Their Buy Rating on Ardelyx (ARDX)October 22 at 8:43 AM | theglobeandmail.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXOctober 21 at 6:53 PM | globenewswire.comSee More Headlines ARDX Stock Analysis - Frequently Asked Questions How have ARDX shares performed this year? Ardelyx's stock was trading at $5.83 at the beginning of 2026. Since then, ARDX stock has decreased by 47.2% and is now trading at $3.08. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. Ardelyx's revenue for the quarter was up 34.3% compared to the same quarter last year. Read the conference call transcript. When did Ardelyx IPO? Ardelyx (ARDX) raised $60 million in an initial public offering on Wednesday, June 18th 2014. The company issued 4,286,000 shares at $13.00-$15.00 per share. Who are Ardelyx's major shareholders? Top institutional investors of Ardelyx include Clay Northam Wealth Management LLC (0.13%), Inspire Investing LLC (0.07%), Vontobel Holding Ltd. (0.01%) and Sterling Capital Management LLC. Insiders that own company stock include David M Mott, Michael Raab, Eric Duane Foster, Justin A Renz, Laura A Williams, Mike Kelliher, Robert Blanks, John E Bishop, Elizabeth A Grammer, James Parker Brady, Susan Hohenleitner, David P Rosenbaum, Joseph James Reilly and Robert Ora Felsch. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR), Pfizer (PFE) and Block (XYZ). Company Calendar Last Earnings8/06/2026Today10/24/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ARDX's financial health is in the Red zone, according to TradeSmith. ARDX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARDX CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees489Year Founded2007Price Target and Rating Average Price Target for Ardelyx$13.90 High Price Target$19.00 Low Price Target$9.00 Potential Upside/Downside+351.3%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.60 million Net Margins-12.35% Pretax Margin-12.30% Return on Equity-36.00% Return on Assets-10.77% Debt Debt-to-Equity Ratio1.69 Current Ratio3.34 Quick Ratio3.15 Sales & Book Value Annual Sales$450.89 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book4.46Miscellaneous Outstanding Shares249,188,000Free Float235,981,000Market Cap$767.50 million OptionableOptionable Beta0.68 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:ARDX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredTrump's bank just got approvedLast month I told investors that a Trump-backed crypto bank could be approved any day. On August 14, it was...Crypto 101 Media | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
